Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer

pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

1991 • 5,979 citations

SH2 domains recognize specific phosphopeptide sequences

1993 • 2,685 citations

Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor

1993 • 1,077 citations

Prognostic Factors in Breast Cancer

2000 • 1,068 citations

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

2000 • 1,034 citations

A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor

1996 • 1,021 citations

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185

1986 • 1,020 citations

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

1987 • 1,015 citations

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 • 981 citations

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

1996 • 772 citations

Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers

1992 • 757 citations

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

1998 • 628 citations

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

1987 • 627 citations

Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer

1998 • 564 citations

Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma

1994 • 555 citations

Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway

1994 • 458 citations

Histological Typing of Breast Tumors

1982 • 448 citations

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1999 • 445 citations

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

1993 • 445 citations

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

1989 • 432 citations

The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor Family

1995 • 364 citations

The erbB3 gene product is a receptor for heregulin.

1994 • 361 citations

Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.

1988 • 321 citations

Involvement of pp60c-src with two major signaling pathways in human breast cancer.

1994 • 273 citations

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.

1998 • 248 citations

The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.

1994 • 246 citations

Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.

1996 • 229 citations

EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.

1988 • 226 citations

A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.

1994 • 198 citations

Novel Activating Mutations in the neu Proto-oncogene Involved in Induction of Mammary Tumors

1994 • 188 citations

The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4

1996 • 167 citations

Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.

1986 • 158 citations

Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

1994 • 144 citations

Oncogenic Activation of p185^neu Stimulates Tyrosine Phosphorylation In Vivo

1988 • 142 citations

Comparison of Mitotic Index, In Vitro Bromodeoxyuridine Labeling, and MIB-1 Assays to Quantitate Proliferation in Breast Cancer

1999 • 141 citations

Oncogenic potential of erbB-2 in human mammary epithelial cells.

1991 • 139 citations

A novel splice variant ofHER2 with increased transformation activity

1998 • 130 citations

The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor

1999 • 128 citations

The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.

1991 • 128 citations

Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.

1988 • 87 citations

Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.

1995 • 85 citations

The role of autophosphorylation in modulation of erbB-2 transforming function.

1990 • 53 citations

The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.

1990 • 52 citations

Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.

1992 • 46 citations

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours

1996 • 43 citations

Evaluation of In Vitro Bromodeoxyuridine Labeling of Breast Carcinomas with the Use of a Commercial Kit

1991 • 31 citations

pS2 protein and steroid hormone receptors in invasive breast carcinomas

1992 • 29 citations

Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.

1992 • 11 citations

Cited By (0)

Loading...